The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RAPP | -4.61% | N/A | N/A | +23% |
| S&P | +12.65% | +91.73% | +13.89% | +26% |
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.26M | -16.9% |
| Market Cap | $1.37B | 82.8% |
| Market Cap / Employee | $19.85M | 0.0% |
| Employees | 69 | 0.0% |
| Net Income | -$26.93M | -53.5% |
| EBITDA | -$29.73M | -38.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $251.46M | 537.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.39M | 908.6% |
| Short Term Debt | $2.48M | 244.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.55% | 0.0% |
| Return On Invested Capital | -34.87% | 4.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.60M | -6.3% |
| Operating Free Cash Flow | -$17.47M | -6.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.01 | 1.20 | 1.45 | 4.11 | 85.00% |
| Price to Tangible Book Value | 2.01 | 1.20 | 1.45 | 4.11 | 85.00% |
| Enterprise Value to EBITDA | -14.83 | -2.83 | -5.28 | -21.03 | 4.78% |
| Return on Equity | -33.1% | -29.4% | -23.4% | - | |
| Total Debt | $1.48M | $7.84M | $11.86M | $11.87M | 619.08% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
